Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G glucosamine drink

This article was originally published in The Tan Sheet

Executive Summary

Elations, a juice drink containing glucosamine and chondroitin that was developed by Procter & Gamble, will begin test marketing in July at Lousiville, Ky. Kroger stores, The Elations Company announces June 22. Elations is marketing the beverage through a licensing agreement and expects to add other retailers at a later date. The firm points to results of the recently GAIT study, which found that glucosamine and chondroitin were effective in treating moderate to severe knee pain caused by osteoarthritis (1"The Tan Sheet" Feb. 27, 2006, p. 5). P&G previously entered the supplement industry when it partnered with Pharmavite to launch Olay Vitamins (2"The Tan Sheet" June 16, 2003, p. 12). Elations is available in raspberry white grape and cranberry apple flavors, and will be sold in six-packs for $7.99...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel